About Anthrax
Pipeline & Programs
Elusys Therapeutics develops advanced medical countermeasures against high-consequence biological threats. Our pipeline encompasses therapeutic and vaccine programs for biological warfare pathogens and infectious disease threats, addressing critical gaps in biodefense preparedness and national security infrastructure.
ANTHIM® (Obiltoxaximab)
Inhalational Anthrax
Monoclonal Antibody
Approved
LAV-BASTA-48
Inhalational Anthrax
Vaccine
Preclinical Development
Undisclosed
Undisclosed Biodefense Indication
Undisclosed
Undisclosed
Drug / Program
Threat Area
Modality
Development Stage
ANTHIM®(obiltoxaximab)
Targeted Neutralization of Inhalational Anthrax
ANTHIM® is Elusys’ monoclonal antibody medical countermeasure designed to bind and neutralize anthrax toxin. Administered in combination with appropriate antibacterial therapy, it addresses inhalational anthrax—widely regarded as the most likely and concerning biological threat to the United States. FDA-approved in 2016 under the Animal Rule and licensed in other global jurisdictions, ANTHIM® has been procured for the U.S. Strategic National Stockpile and other allied government stockpiles around the world.
